Clinical trials: G-CSF
Extragonadal Germ Cell Tumor, Teratoma
Combination Chemotherapy in Treating Men With Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor
- Trial name
- NCT00003643
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 69 sites in Austria, Belgium and 12 more
- Volunteers
- 498 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Soft-tissue Sarcoma, Triple Negative Breast Cancer
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small…
- Conditions
- Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT07064018
- Testing
- Spedox-6, Pegfilgrastim, Filgrastim
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, Irvine
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00003776
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or by killing them. It also prepares the patient's bone marrow for the stem cell transplant.
- Trial name
- NCT00526318
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 68 sites in Germany, Switzerland
- Volunteers
- 360 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Graft Versus Host Disease, Leukemia
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00002833
- Testing
- Filgrastim, Cladribine, Cyclosporine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Acute Myeloid Leukemia
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
The hypothesis is that the replacement of the standard fludarabine and cytarabine based therapy by azacytidine could result in an improvement of RFS and OS rates in the experimental arm.
- Trial name
- FLUGAZA (NCT02319135)
- Testing
- Azacitadine, Fludarabine, Cytarabine
- Where
- Spain
- Volunteers
- 289 people
- Sponsor
- PETHEMA Foundation
Breast Cancer
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Trial name
- NCT00020176
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
- Trial name
- NCT01564784
- Testing
- inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine)
- Where
- 198 sites in United States, Argentina and 18 more
- Volunteers
- 326 people
- Sponsor
- Pfizer
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Mantle Cell Lymphoma
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.
- Trial name
- NCT02858258
- Testing
- R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT conditioning
- Where
- 112 sites in Denmark, Germany and 3 more
- Volunteers
- 870 people
- Sponsor
- Prof. Dr. M. Dreyling (co-chairman)
Lymphoma, Lymphoblastic
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia.
- Trial name
- NCT00199017
- Testing
- Dexamethasone/Prednisolone, Cyclophosphamide, Vincristine
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Infertility
Diafert® for Embryo Selection and Fertility Improvement
Prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.
- Trial name
- DESTINy (NCT02593461)
- Testing
- Daifert, Control Group
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Forest Laboratories
Pediatric Hematologic Malignancies
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft…
- Trial name
- NCT05011422
- Testing
- Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion.
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT04713956
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU)
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Peripheral T-Cell Lymphoma
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation
- Trial name
- NCT01806337
- Testing
- Alemtuzumab
- Volunteers
- 41 people
- Sponsor
- University of Göttingen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.